EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial

Sang Wook Son, Patrick Brunner, Lisa Vansaghi, Evangeline Pierce, Marco Pontes Marco Pontes, Jennifer Proper, Renata Gontijo Lima, Lucia Seminario-Vidal Lucia Seminario-Vidal, Sheila Okoroanyanwu, Jonathan Silverberg, Chia-Yu Chu, Claudia Calderón-Rocher und 5 weitere

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s837

DOI: 10.25251/aga4xb49 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Sang Wook Son und 16 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic hand and foot dermatitis (AHFD) is a common, recalcitrant, and debilitating manifestation of atopic dermatitis (AD) driven by type 2 inflammation, including overexpression of interleukin-13, with pruritus and pain as primary symptoms. Despite substantial impact on quality of life (QoL) and work productivity, systemic treatment options for AHFD remain limited.

Objectives

To evaluate efficacy and safety of lebrikizumab, a selective interleukin-13-inhibitor, as monotherapy in adults and adolescents with moderate-to-severe AHFD.

Methods

ADtouch (NCT06921759) was a multi-center, randomized, double-blind, placebo-controlled, parallel-group phase 3b trial evaluating lebrikizumab versus placebo in adults (≥18 years) and adolescents (≥12 to

Zitieren

APA

Son, S. W., Brunner, P., Vansaghi, L., Pierce, E., Pontes, M. P. M., Proper, J., Lima, R. G., Seminario-Vidal, L. S. L., Okoroanyanwu, S., Silverberg, J., Chu, C., Calderón-Rocher, C., Luna, P., Wiseman, M., Masuda, K., Laquer, V., & Simpson, E. (2026). Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial. SKIN The Journal of Cutaneous Medicine, 10(6), s837. https://doi.org/10.25251/aga4xb49

Vancouver

Son SW, Brunner P, Vansaghi L, Pierce E, Pontes MPM, Proper J, et al. Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s837. doi:10.25251/aga4xb49

BibTeX
@article{Son2026,
  author = {Son, Sang Wook and Brunner, Patrick and Vansaghi, Lisa and Pierce, Evangeline and Pontes, Marco Pontes Marco and Proper, Jennifer and Lima, Renata Gontijo and Seminario-Vidal, Lucia Seminario-Vidal Lucia and Okoroanyanwu, Sheila and Silverberg, Jonathan and Chu, Chia-Yu and Calderón-Rocher, Claudia and Luna, Paula and Wiseman, Marni and Masuda, Koji and Laquer, Vivian and Simpson, Eric},
  title = {Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s837},
  doi = {10.25251/aga4xb49}
}
Kostenlos starten →